Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1Phase 3 1Phase 2 1

Status

Completed 4Terminated 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5Other hematologic neoplasm 2

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1

Interventions

Trastuzumab 260Paclitaxel 216Cyclophosphamide 173Docetaxel 146Letrozole 126Fulvestrant 121Capecitabine 121Doxorubicin 111Carboplatin 98Bevacizumab 90exemestane 88Anastrozole 85Tamoxifen 77Lapatinib 77pembrolizumab 68Albumin-Bound Paclitaxel 67pertuzumab 62palbociclib 60Taxes 59Gemcitabine 57eribulin 48130-nm albumin-bound paclitaxel 47Radiotherapy 46Everolimus 44Ado-Trastuzumab Emtansine 43Vinorelbine 39ixabepilone 32Epirubicin 30Cisplatin 30pegfilgrastim 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has results × Anthracyclines × Breast × Clear all
NCT02521363 2025-08-22

Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase NA Completed
11 enrolled 7 charts
Breast

Breast Neoplasms

NCT04109066 2025-01-08

CheckMate 7FL

Bristol-Myers Squibb

Phase 3 Completed
521 enrolled 17 charts
Breast

Breast Neoplasms, Neoplasms

NCT00712881 2024-02-23

Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
126 enrolled 16 charts
Breast

Breast Neoplasms

NCT02622074 2020-09-10

KEYNOTE 173

Merck Sharp & Dohme LLC

Phase 1 Completed
60 enrolled 26 charts
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT02561832 2019-02-20

A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer

AstraZeneca

Phase 1 Terminated
15 enrolled 8 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡